Volume | 12,377 |
|
|||||
News | - | ||||||
Day High | 4.59 | Low High |
|||||
Day Low | 4.48 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | EGRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.48 | 4.48 | 4.59 | 4.48 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
243 | 12,377 | $ 4.52 | $ 55,909 | - | 4.10 - 30.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:09:51 | 20 | $ 4.55 | USD |
Eagle Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
58.96M | 12.99M | - | 316.61M | 35.64M | 2.74 | 1.65 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eagle Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EGRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.79 | 5.26 | 4.28 | 4.82 | 183,377 | -0.24 | -5.01% |
1 Month | 5.21 | 5.40 | 4.28 | 4.89 | 161,224 | -0.66 | -12.67% |
3 Months | 5.35 | 6.81 | 4.28 | 5.47 | 186,111 | -0.80 | -14.95% |
6 Months | 13.65 | 14.78 | 4.10 | 5.92 | 219,598 | -9.10 | -66.67% |
1 Year | 27.86 | 30.40 | 4.10 | 11.52 | 188,489 | -23.31 | -83.67% |
3 Years | 43.97 | 58.25 | 4.10 | 28.21 | 152,671 | -39.42 | -89.65% |
5 Years | 47.69 | 64.94 | 4.10 | 36.86 | 152,349 | -43.14 | -90.46% |
Eagle Pharmaceuticals Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. |